These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 16450343)

  • 21. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylation as a target for radiosensitization.
    Cerna D; Camphausen K; Tofilon PJ
    Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
    Weidle UH; Grossmann A
    Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
    Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
    Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Histone-deacetylases inhibitors: from TSA to SAHA].
    Peixoto P; Lansiaux A
    Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
    Chung YL; Lee MY; Pui NN
    Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
    Fang JY
    J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the epigenome for the treatment and prevention of lung cancer.
    Schrump DS; Nguyen DM
    Semin Oncol; 2005 Oct; 32(5):488-502. PubMed ID: 16210090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
    Zubia A; Ropero S; Otaegui D; Ballestar E; Fraga MF; Boix-Chornet M; Berdasco M; Martinez A; Coll-Mulet L; Gil J; Cossío FP; Esteller M
    Oncogene; 2009 Mar; 28(11):1477-84. PubMed ID: 19169274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors.
    Ellis DJ; Lawman ZK; Bonham K
    Biochem Biophys Res Commun; 2008 Mar; 367(3):656-62. PubMed ID: 18179771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
    Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of novel hydroxamate and non-hydroxamate histone deacetylase inhibitors.
    Curtin ML
    Curr Opin Drug Discov Devel; 2004 Nov; 7(6):848-68. PubMed ID: 15595445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis.
    Zhang Y; Adachi M; Kawamura R; Imai K
    Cell Death Differ; 2006 Jan; 13(1):129-40. PubMed ID: 15947789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HDAC family: What are the cancer relevant targets?
    Witt O; Deubzer HE; Milde T; Oehme I
    Cancer Lett; 2009 May; 277(1):8-21. PubMed ID: 18824292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.